Patents Assigned to Gilead Sciences, Inc.
-
Patent number: 12122776Abstract: The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.Type: GrantFiled: May 12, 2023Date of Patent: October 22, 2024Assignee: Gilead Sciences, Inc.Inventors: Lan Jiang, David W. Lin, Michael L. Mitchell, Ezra Roberts, Gregg M. Schwarzwalder
-
Patent number: 12122764Abstract: The present disclosure relates to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2, including cancer.Type: GrantFiled: December 20, 2022Date of Patent: October 22, 2024Assignee: Gilead Sciences, Inc.Inventors: Peter A. Blomgren, Zhimin Du, Musong Kim, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani
-
Patent number: 12122765Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.Type: GrantFiled: June 5, 2023Date of Patent: October 22, 2024Assignee: Gilead Sciences, Inc.Inventors: Anna Michelle Wagner, Scott Alan Wolckenhauer
-
Patent number: 12121511Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.Type: GrantFiled: January 27, 2021Date of Patent: October 22, 2024Assignee: Gilead Sciences, Inc.Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
-
Patent number: 12121529Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.Type: GrantFiled: November 16, 2023Date of Patent: October 22, 2024Assignee: Gilead Sciences, Inc.Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
-
Patent number: 12116380Abstract: Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.Type: GrantFiled: August 16, 2022Date of Patent: October 15, 2024Assignee: Gilead Sciences, Inc.Inventors: Byoung-Kwon Chun, Michael O. Clarke, Deeba Ensan, Rao V. Kalla, Richard L Mackman, Jagadeesh N. Manda, Devan Naduthambi, Dustin S. Siegel
-
Patent number: 12110294Abstract: The present disclosure provides pyrimidine dione compounds of Formula I and pharmaceutical compositions thereof, for treating cancer, including solid tumors either-used alone or in combination with other anti-cancer agents.Type: GrantFiled: April 29, 2021Date of Patent: October 8, 2024Assignee: Gilead Sciences, Inc.Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L. Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Hon C. Hui, Richard L. Mackman, Michael R. Mish, Scott D. Schroeder, Nathan D. Shapiro, Dustin S. Siegel, Doris T. Tang, Hai Yang
-
Patent number: 12110305Abstract: Compounds, compositions, and method useful for treating a viral infection, such as human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, are disclosed. In particular, prodrugs of phosphonamide nucleotide analogues and methods for their preparation and use as therapeutic or prophylactic agents are disclosed.Type: GrantFiled: August 5, 2021Date of Patent: October 8, 2024Assignee: Gilead Sciences, Inc.Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Devan Naduthambi, Neil H. Squires
-
Patent number: 12102625Abstract: Disclosed herein are novel solid forms of FXR agonists. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by FXR. The disclosure also relates to methods for obtaining such solid forms.Type: GrantFiled: October 31, 2022Date of Patent: October 1, 2024Assignee: Gilead Sciences, Inc.Inventors: Derek M. Dalton, Peter C. Fung, Nolan Griggs, Jeffrey N. Hemenway, Olga V. Lapina, Matthew M. Logan, Sean T. Neville, Bryan J. Reynolds, Hui-Wen Shih, Anna M. Wagner
-
Patent number: 12102677Abstract: Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 V3 glycan region.Type: GrantFiled: May 18, 2020Date of Patent: October 1, 2024Assignee: GILEAD SCIENCES, INC.Inventors: Brian Moldt, Craig S. Pace
-
Publication number: 20240307502Abstract: The present disclosure relates to a method of treating non-alcoholic steatohepatitis (NASH) comprising administering to a subject with NASH a combination therapy comprising semaglutide, firsocostat, and/or cilofexor.Type: ApplicationFiled: May 24, 2024Publication date: September 19, 2024Applicants: Gilead Sciences, Inc., Novo Nordisk A/SInventors: Constantine Stephen Djedjos, Bryan John McColgan, Robert Paul Myers, Gangadharan Mani Subramanian, Lene Melchiorsen, Morten Hansen
-
Patent number: 12091404Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: GrantFiled: March 9, 2022Date of Patent: September 17, 2024Assignee: Gilead Sciences, Inc.Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
-
Patent number: 12091426Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.Type: GrantFiled: November 9, 2022Date of Patent: September 17, 2024Assignees: Nurix Therapeutics, Inc., Gilead Sciences, Inc.Inventors: John Buell, Frederick Cohen, Ryan Pemberton, Hunter P. Shunatona, Lan Wang, Mark Edward Zak
-
Patent number: 12091420Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.Type: GrantFiled: October 3, 2023Date of Patent: September 17, 2024Assignee: Gilead Sciences, Inc.Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Jessica L. Mckinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
-
Patent number: 12084467Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.Type: GrantFiled: December 2, 2022Date of Patent: September 10, 2024Assignee: Gilead Sciences, Inc.Inventors: Zhimin Du, Julie Farand, Tezcan Guney, Darryl Kato, John O. Link, James B. C. Mack, Dong Min Mun, William J. Watkins, Jennifer R. Zhang
-
Patent number: 12084455Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.Type: GrantFiled: April 7, 2021Date of Patent: September 10, 2024Assignee: Gilead Sciences, Inc.Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
-
Patent number: 12084510Abstract: Herein described are antibodies to epidermal growth factor receptor (EGER) having an EGER binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.Type: GrantFiled: February 21, 2020Date of Patent: September 10, 2024Assignees: Gilead Sciences, Inc., National Research Council of CanadaInventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe
-
Patent number: 12077537Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.Type: GrantFiled: February 15, 2023Date of Patent: September 3, 2024Assignee: Gilead Sciences, Inc.Inventors: Chienhung Chou, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
-
Patent number: 12070455Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.Type: GrantFiled: September 8, 2022Date of Patent: August 27, 2024Assignee: Gilead Sciences, Inc.Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore
-
Patent number: 12060351Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.Type: GrantFiled: August 13, 2019Date of Patent: August 13, 2024Assignee: Gilead Sciences, Inc.Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, Marina Shatskikh, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel